Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump
Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...
A common blood test for ovarian cancer is more likely to fall short for Black and Native American women
A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
The Healthy @Reader's Digest5d
“How I Knew I Had Ovarian Cancer”: A Patient’s Story Reveals an Unexpected Benefit of Daily Exercise
A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...
Corcept Therapeutics Shares Soar on Positive Ovarian Cancer Treatment Trial Results
Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...
Blood test for ovarian cancer misses some Black and Native American patients, study finds
A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...
Explore more
J&J’s (JNJ) Bankruptcy Plan to Settle Talc Cancer Claims Faces Rejection
American pharmaceutical giant Johnson & Johnson (JNJ) has once again faced rejection on its $10 billion plan to settle thousands of ...
WebMD10d
What to Know About Ovarian Cancer Recurrence
After you’ve gone through ovarian cancer treatment, your doctor will work with you to make sure you stay well. But sometimes the cancer returns. Doctors call this “recurrence.” To check for ...
The Associated Press on MSN12d
Blood test for ovarian cancer misses some Black, Native American patients: Study
A new study finds that a common blood test for ovarian cancer may miss some Black and Native American patients, delaying ...